SingapOre Lung cancer Screening Through Integrating CT with other biomarkErs (SOLSTICE) Study

Every year, the world commemorates Lung Cancer Awareness Month in November to increase awareness on the disease. Lung cancer remains the most diagnosed cancer across the globe. According to the Singapore Cancer Registry Report 2019, lung cancer is the 3rd most commonly diagnosed cancer among men and women in Singapore, with more than 60% diagnosed a Stage IV between 2015 and 2019. It has the highest cancer mortality rate among Singaporean men and third highest cancer mortality rate among Singaporean women. Lung cancer typically has no symptoms until the advanced stages, and is hence often not detected until late.

Low-dose computed tomography (LDCT) screening of lung cancer is intensively being studied and implemented internationally as means to detect lung cancer early.

The purpose of the SOLSTICE study is to examine if Low Dose Computed Tomography (LDCT) scan and blood-based biomarker test are effective for lung cancer screening in high- and/or at-risk local populations. This study will be piloted on SingHealth.

WHO IS ELIGIBLE?

Sign up for the study and be part of our lung cancer screening efforts today! Please take a few minutes to complete a short questionnaire and our research coordinators will be in contact if you are eligible for the study: https://for.sg/solstice

If you have questions pertaining to the study, please email to lung.cancer.screening@singhealth.com.sg.